PACB
Pacific Biosciences of California, Inc. NASDAQ Listed Oct 27, 2010$1.65
Mkt Cap $498.3M
52w Low $0.85
42.6% of range
52w High $2.73
50d MA $1.48
200d MA $1.69
P/E (TTM)
-0.9x
EV/EBITDA
-36.7x
P/B
89.9x
Debt/Equity
142.0x
ROE
-10214.5%
P/FCF
-4.9x
RSI (14)
—
ATR (14)
—
Beta
2.33
50d MA
$1.48
200d MA
$1.69
Avg Volume
6.4M
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
1305 O’Brien Drive · Menlo Park, CA 94025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.17 | -0.03 | +82.4% | 1.65 | -7.9% | -14.5% | — | — | — | — | — |
| Feb 12, 2026 | AMC | -0.19 | -0.12 | +36.8% | 1.84 | +2.7% | -7.1% | -7.6% | +3.2% | +3.1% | -4.2% | — |
| Nov 5, 2025 | AMC | -0.16 | -0.12 | +25.0% | 1.92 | -5.7% | -7.3% | -1.1% | +0.0% | +5.7% | -6.5% | — |
| Aug 7, 2025 | AMC | -0.18 | -0.13 | +27.8% | 1.26 | +15.1% | +7.1% | -6.7% | -4.0% | +5.8% | -3.9% | — |
| May 8, 2025 | AMC | -0.19 | -0.15 | +21.1% | 1.20 | -0.8% | -6.7% | -1.8% | +4.5% | -4.3% | -3.6% | — |
| Feb 13, 2025 | AMC | -0.20 | -0.20 | +0.0% | 1.48 | -3.4% | +25.0% | +1.1% | -5.3% | -7.3% | -6.1% | — |
| Nov 7, 2024 | AMC | -0.22 | -0.22 | +0.0% | 2.45 | -11.0% | -6.1% | +7.0% | -10.2% | -10.4% | -6.1% | — |
| Aug 7, 2024 | AMC | -0.24 | -0.20 | +16.7% | 1.53 | -11.1% | +9.2% | -4.8% | -10.1% | +4.2% | -9.4% | — |
| May 9, 2024 | AMC | -0.28 | -0.29 | -3.6% | 1.72 | +0.0% | +2.9% | +9.0% | +15.5% | -3.6% | +1.9% | — |
| Feb 15, 2024 | AMC | -0.29 | -0.31 | -6.9% | 6.67 | -4.0% | -13.9% | -7.8% | -4.0% | +1.0% | -0.4% | — |
| Oct 30, 2023 | AMC | -0.33 | -0.26 | +21.2% | 7.11 | -5.3% | -13.1% | -3.4% | +9.2% | +10.7% | -5.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Barclays | Maintains | Underweight → Underweight | — | $1.45 | $1.47 | +1.4% | +8.3% | +1.9% | +1.9% | +3.7% | +3.0% |
| Mar 6 | Barclays | Downgrade | Equal Weight → Underweight | — | $1.52 | $1.46 | -3.9% | -9.2% | +0.7% | -1.4% | -1.5% | -5.9% |
| Dec 15 | Barclays | Maintains | Equal Weight → Equal Weight | — | $2.12 | $2.15 | +1.4% | +0.0% | -4.7% | -4.5% | -2.6% | -2.1% |
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $1.76 | $1.78 | +1.1% | +5.7% | -6.5% | -6.3% | -1.2% | -2.5% |
| Nov 10 | Stephens & Co. | Maintains | Overweight → Overweight | — | $1.76 | $1.83 | +4.0% | +0.0% | +5.7% | -6.5% | -6.3% | -1.2% |
| Aug 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $1.35 | $1.36 | +0.7% | -6.7% | -4.0% | +5.8% | -3.9% | +6.5% |
| Jun 25 | Barclays | Maintains | Equal Weight → Equal Weight | — | $1.20 | $1.18 | -1.7% | +1.7% | +5.7% | +0.0% | -3.9% | +4.0% |
| May 15 | Stephens & Co. | Maintains | Overweight → Overweight | — | $1.10 | $1.10 | +0.0% | -3.6% | -2.8% | -1.0% | +0.0% | -3.8% |
| May 15 | Piper Sandler | Maintains | Neutral → Neutral | — | $1.10 | $1.10 | +0.0% | -3.6% | -2.8% | -1.0% | +0.0% | -3.8% |
| Apr 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.45 | $1.45 | +0.0% | -4.8% | -1.4% | -2.9% | -3.8% | -5.5% |
| Mar 25 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $1.33 | $1.32 | -0.8% | -1.5% | -3.1% | -2.4% | -8.1% | +3.5% |
| Feb 20 | Piper Sandler | Maintains | Neutral → Neutral | — | $1.77 | $1.75 | -1.1% | -7.3% | -6.1% | +5.8% | -4.3% | +4.5% |
| Feb 18 | Stephens & Co. | Maintains | Overweight → Overweight | — | $1.85 | $1.84 | -0.5% | +1.1% | -5.3% | -7.3% | -6.1% | +5.8% |
| Feb 18 | Goldman Sachs | Maintains | Neutral → Neutral | — | $1.85 | $1.84 | -0.5% | +1.1% | -5.3% | -7.3% | -6.1% | +5.8% |
| Feb 14 | Stephens & Co. | Maintains | Overweight → Overweight | — | $1.48 | $1.43 | -3.4% | +25.0% | +1.1% | -5.3% | -7.3% | -6.1% |
| Jan 23 | Goldman Sachs | Maintains | Neutral → Neutral | — | $1.81 | $1.76 | -2.8% | -8.8% | +2.4% | -1.2% | -3.6% | -3.1% |
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $2.30 | $2.34 | +1.7% | +7.0% | -10.2% | -10.4% | -6.1% | -14.0% |
| Nov 11 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $2.30 | $2.34 | +1.7% | +7.0% | -10.2% | -10.4% | -6.1% | -14.0% |
| Nov 11 | UBS | Downgrade | Buy → Neutral | — | $2.30 | $2.34 | +1.7% | +7.0% | -10.2% | -10.4% | -6.1% | -14.0% |
| Aug 28 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $1.47 | $1.46 | -0.7% | -8.2% | +0.7% | +0.7% | -2.2% | -1.5% |
| Aug 13 | Stephens & Co. | Maintains | Overweight → Overweight | — | $1.43 | $1.48 | +3.5% | +4.2% | -9.4% | +25.2% | -7.7% | +2.6% |
| Aug 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $1.59 | $1.58 | -0.6% | -10.1% | +4.2% | -9.4% | +25.2% | -7.7% |
| Aug 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.53 | $1.36 | -11.1% | +9.2% | -4.8% | -10.1% | +4.2% | -9.4% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.53 | $1.36 | -11.1% | +9.2% | -4.8% | -10.1% | +4.2% | -9.4% |
| May 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.23 | $2.42 | +8.5% | -3.6% | +1.9% | -7.8% | -5.0% | -4.7% |
| May 13 | Piper Sandler | Maintains | Neutral → Neutral | — | $1.77 | $1.81 | +2.3% | +9.0% | +15.5% | -3.6% | +1.9% | -7.8% |
| May 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $1.72 | $1.72 | +0.0% | +2.9% | +9.0% | +15.5% | -3.6% | +1.9% |
| Apr 22 | JP Morgan | Downgrade | Overweight → Neutral | — | $1.55 | $1.49 | -3.9% | +0.6% | -5.8% | -7.5% | +1.5% | +6.5% |
| Apr 19 | Goldman Sachs | Maintains | Neutral → Neutral | — | $1.46 | $1.47 | +0.7% | +6.2% | +0.6% | -5.8% | -7.5% | +1.5% |
| Apr 18 | Goldman Sachs | Downgrade | Buy → Neutral | — | $1.40 | $1.39 | -0.7% | +4.3% | +6.2% | +0.6% | -5.8% | -7.5% |
| Apr 18 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $1.40 | $1.39 | -0.7% | +4.3% | +6.2% | +0.6% | -5.8% | -7.5% |
| Apr 18 | Bernstein | Maintains | Outperform → Outperform | — | $1.40 | $1.39 | -0.7% | +4.3% | +6.2% | +0.6% | -5.8% | -7.5% |
| Apr 17 | TD Cowen | Maintains | Buy → Buy | — | $1.40 | $1.50 | +7.1% | +0.0% | +4.3% | +6.2% | +0.6% | -5.8% |
| Apr 10 | Goldman Sachs | Maintains | Buy → Buy | — | $3.61 | $3.42 | -5.3% | -7.8% | +1.5% | -6.2% | -10.4% | -50.7% |
| Apr 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $3.61 | $3.42 | -5.3% | -7.8% | +1.5% | -6.2% | -10.4% | -50.7% |
| Mar 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.84 | $3.79 | -1.3% | -4.2% | -1.9% | -2.5% | +5.7% | +0.8% |
| Feb 16 | UBS | Maintains | Buy → Buy | — | $6.67 | $6.40 | -4.0% | -13.9% | -7.8% | -4.0% | +1.0% | -0.4% |
| Nov 17 | UBS | Upgrade | Neutral → Buy | — | $7.59 | $7.82 | +3.0% | +10.7% | +2.1% | -3.5% | +1.0% | +2.3% |
| Nov 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $7.22 | $7.19 | -0.4% | -5.8% | +1.2% | -2.8% | -2.5% | +0.0% |
| Oct 31 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $7.11 | $6.73 | -5.3% | -13.1% | -3.4% | +9.2% | +10.7% | -5.8% |
| Oct 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.11 | $6.73 | -5.3% | -13.1% | -3.4% | +9.2% | +10.7% | -5.8% |
| Oct 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.26 | $7.31 | +0.7% | +0.6% | -7.9% | +6.4% | -0.6% | +0.0% |
| Oct 16 | Piper Sandler | Maintains | Neutral → Neutral | — | $7.98 | $7.78 | -2.5% | +0.0% | +2.9% | -6.8% | -2.7% | -0.7% |
| Sep 29 | Barclays | Maintains | Equal Weight → Equal Weight | — | $8.36 | $8.46 | +1.2% | -0.1% | -3.6% | -2.6% | +2.2% | +2.6% |
| Sep 26 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $8.46 | $8.45 | -0.1% | -2.7% | +1.6% | +0.0% | -0.1% | -3.6% |
| Aug 22 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $10.35 | $10.37 | +0.2% | -0.8% | +2.1% | -4.1% | -1.4% | +0.0% |
| Aug 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.52 | $11.64 | +1.0% | +5.7% | -2.0% | +0.4% | -2.6% | +2.0% |
| Aug 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.52 | $12.75 | +1.8% | -8.0% | +5.7% | -2.0% | +0.4% | -2.6% |
| Jun 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.49 | $13.59 | +0.7% | +0.7% | +0.3% | +2.6% | -0.4% | -1.0% |
| May 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $12.03 | $12.35 | +2.7% | -1.0% | +2.0% | +0.3% | +2.1% | -1.7% |
No insider trades available.
8-K · 5.02
!!! Very High
Pacific Biosciences of California, Inc. -- 8-K 5.02: Executive Change
Pacific Biosciences' Chief Accounting Officer Michele Farmer is resigning effective March 21, 2026, which may signal leadership instability but doesn't immediately impact core operations or financial strategy.
Mar 6
8-K · 5.02
!!! Very High
Pacific Biosciences of California, Inc. -- 8-K 5.02: Executive Change
Pacific Biosciences appointed Christopher Gibson as a Class I director, strengthening its board with additional oversight and governance capabilities.
Mar 5
8-K
Pacific Biosciences of California, Inc. -- 8-K Filing
Pacific Biosciences reported its fourth quarter and full year 2025 financial results, providing investors with updated performance metrics and non-GAAP reconciliations for evaluating the company's operational and financial health.
Feb 12
8-K · 5.02
!!! Very High
Pacific Biosciences of California, Inc. -- 8-K 5.02: Executive Change
Pacific Biosciences appointed an interim leader to oversee operations and R&D functions, signaling potential executive transition amid possible operational concerns requiring temporary leadership restructuring.
Feb 3
8-K · 2.01
!!! Very High
Pacific Biosciences of California, Inc. -- 8-K 2.01: Acquisition Completed
Pacific Biosciences completed an asset sale generating $48.1 million in net proceeds, while facing a 2026 milestone payment obligation tied to its August 2023 Apton acquisition.
Feb 2
Data updated apr 26, 2026 6:27pm
· Source: massive.com